Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone De

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. META
2. SPY
3. USO
4. MU
5. MSFT
6. COST
7. IONS
8. AVAV
9. SKHY
10. ORCL

Go back to Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone De

Ascendis Pharma (ASND) PT Raised to $185 at Cantor Fitzgerald

March 4, 2019 10:33 AM EST

Cantor Fitzgerald analyst Alethia Young raised the price target on Ascendis Pharma (NASDAQ: ASND) to $185.00 (from $100.00) while maintaining a Overweight rating.

... More